Nicotinamide adenine dinucleotide (NAD+) is a crucial coenzyme found in every cell in your body, involved in hundreds of metabolic processes. As we age, NAD+ levels decline significantly—some estimates suggest a 50% reduction between the ages of 40 and 60—which is linked to various age-related diseases and functional decline. To combat this, many people turn to NAD+ precursors like Nicotinamide Mononucleotide (NMN) and Nicotinamide Riboside (NR). This article compares NMN and NR, examining the science behind each to help you understand which might be best for your longevity and healthspan goals.
Written by: Vik Chadha, Founder of Finding Answers To. Content is regularly reviewed and updated based on the latest peer-reviewed research.
What is NAD+ and Why Does It Decline?
NAD+ is one of the most abundant and essential molecules in human biology. It participates in over 500 enzymatic reactions and is indispensable for converting the food you eat into cellular energy through processes like glycolysis, the citric acid cycle, and oxidative phosphorylation. Without adequate NAD+, your mitochondria—the powerhouses of your cells—cannot function efficiently, leading to fatigue, metabolic dysfunction, and accelerated aging.
Beyond energy production, NAD+ is critical for DNA repair. Every day, your DNA sustains tens of thousands of lesions from oxidative stress, UV radiation, and normal metabolic byproducts. Enzymes called PARPs (poly ADP-ribose polymerases) consume NAD+ to repair this damage. When NAD+ levels are low, DNA repair slows, allowing mutations to accumulate—a hallmark of aging and cancer risk.
NAD+ is also essential for activating sirtuins, a family of seven proteins (SIRT1–SIRT7) that regulate gene expression, inflammation, stress resistance, and metabolic health. As Eric Verdin's landmark review in Sciencedescribed, sirtuins are “NAD+-dependent deacylases” that link cellular metabolism to epigenetic regulation and aging (Verdin, 2015). When NAD+ declines, sirtuin activity drops, contributing to chronic inflammation, insulin resistance, and neurodegeneration.
The decline of NAD+ with age appears to be driven by multiple factors: increased activity of CD38 (an enzyme that degrades NAD+), chronic inflammation, and reduced biosynthesis. This decline is now considered one of the central drivers of the aging process, which is why restoring NAD+ levels has become a major focus of longevity science.
NMN: Mechanism and Evidence
Nicotinamide Mononucleotide (NMN) is a naturally occurring nucleotide found in small quantities in foods like broccoli, cabbage, edamame, and avocado. In the NAD+ biosynthesis pathway, NMN sits one step away from NAD+ itself. The enzyme nicotinamide mononucleotide adenylyltransferase (NMNAT) converts NMN directly into NAD+, making it one of the most direct precursors available.
NMN gained widespread attention through the work of Harvard geneticist David Sinclair, whose laboratory demonstrated that NMN supplementation could reverse age-related vascular decline, improve insulin sensitivity, and restore mitochondrial function in aged mice. These dramatic animal results prompted significant interest in human trials.
The most rigorous human clinical trial to date was published in Science by Yoshino and colleagues in 2021. This randomized, double-blind, placebo-controlled study enrolled 25 postmenopausal, prediabetic women who received 250 mg of NMN daily for 10 weeks. The results showed that NMN supplementation increased muscle insulin sensitivity by approximately 25%, improved skeletal muscle remodeling, and upregulated pathways related to muscle growth and structure (Yoshino et al., 2021). While the study was small, its rigorous design and publication in a top-tier journal gave the NMN field significant credibility.
Additional human studies have demonstrated that oral NMN supplementation safely raises blood NAD+ levels in a dose-dependent manner, with doses ranging from 250 mg to 1,200 mg per day showing good tolerability. Japanese clinical trials have further confirmed the safety profile in healthy adults. However, large-scale, long-term outcome studies are still underway, and the field awaits more data on hard clinical endpoints like disease incidence or mortality.
One important consideration is that NMN was briefly the subject of regulatory controversy in the United States. In late 2022, the FDA indicated that NMN might be classified as an investigational new drug rather than a dietary supplement, which led to temporary market uncertainty. As of 2026, NMN remains widely available, but consumers should purchase from reputable manufacturers who provide third-party testing certificates.
NR: Mechanism and Evidence
Nicotinamide Riboside (NR) is another form of vitamin B3 that serves as an NAD+ precursor. Found naturally in trace amounts in dairy milk, NR requires two enzymatic steps to become NAD+: first, NR kinases (NRK1 and NRK2) phosphorylate NR into NMN, and then NMNAT converts NMN into NAD+. Despite this extra step, NR has been shown to effectively raise NAD+ levels in human tissues.
NR has a significant head start over NMN in terms of commercial development and clinical research, largely thanks to ChromaDex, the company that developed and patented the NR supplement branded as Niagen. ChromaDex invested heavily in clinical trials, safety studies, and FDA notifications, establishing NR as the first commercially available NAD+ precursor with “New Dietary Ingredient” status and Generally Recognized As Safe (GRAS) designation.
A landmark study by Martens and colleagues, published in Nature Communicationsin 2018, demonstrated that chronic NR supplementation (1,000 mg/day for six weeks) was well-tolerated in healthy middle-aged and older adults (aged 55–79). Participants showed a significant increase in whole-blood NAD+ levels of approximately 60%, along with trends toward reduced blood pressure and arterial stiffness (Martens et al., 2018). While the blood pressure findings did not reach statistical significance in this small cohort of 24 participants, the direction of the results was encouraging and prompted larger follow-up trials.
The NRPT (Nicotinamide Riboside and Pterostilbene) trial further explored NR's effects, combining it with pterostilbene (a polyphenol related to resveratrol). This study confirmed that NR-based supplementation could sustainably increase NAD+ levels in humans, though the addition of pterostilbene raised LDL cholesterol in some participants, highlighting the need for careful formulation choices.
More recent NR research has explored applications in heart failure, kidney injury, and neurodegenerative disease. While results have been mixed—a 2023 trial in heart failure patients did not show improvements in cardiac function despite raising NAD+ levels—the overall safety data for NR remains strong, with consistent evidence that it raises NAD+ without serious adverse effects.
Head-to-Head Comparison
While both NMN and NR effectively raise NAD+ levels, there are meaningful differences to consider when choosing between them:
Bioavailability
NMN is a larger molecule than NR, which initially raised questions about whether it could be absorbed intact through the gut. Research published in 2019 identified the Slc12a8 transporter, which appears to facilitate direct NMN uptake in the small intestine. NR, being smaller, is readily absorbed but must be phosphorylated before it can become NMN and then NAD+. In practice, both compounds have demonstrated the ability to raise blood NAD+ levels in human studies, though direct head-to-head pharmacokinetic comparisons remain limited.
Cost
NR products (particularly the patented Niagen form) have historically been more expensive on a per-dose basis, partly due to ChromaDex's patent protection and licensing fees. NMN prices have dropped considerably as more manufacturers entered the market, though quality varies significantly. As of 2026, a month's supply of reputable NMN (250–500 mg/day) typically costs between $30 and $60, while NR (300–1,000 mg/day) ranges from $40 to $80.
Research Maturity
NR has the advantage of a longer track record in human clinical trials, with more published safety and efficacy data. NMN research is catching up rapidly, with dozens of registered clinical trials now completed or underway. Both molecules benefit from strong preclinical evidence in animal models, but NR currently has the deeper human evidence base.
Dosing
Common dosages for NMN range from 250 mg to 1,000 mg per day, with most clinical trials using 250–500 mg. NR studies have typically used higher doses of 300–1,000 mg per day. Both are generally taken in the morning, as NAD+ plays a role in circadian rhythm regulation and evening dosing may interfere with sleep in some individuals.
Safety and Side Effects
Both NMN and NR have demonstrated favorable safety profiles in clinical trials. The most commonly reported side effects are mild and include nausea, bloating, diarrhea, and skin flushing—symptoms typical of vitamin B3 compounds. These side effects tend to resolve with continued use or dose reduction.
There are theoretical concerns that boosting NAD+ could fuel the growth of existing cancers, since cancer cells are highly metabolically active and rely on NAD+ for rapid proliferation. However, no clinical trial of NMN or NR has reported increased cancer incidence. Some preclinical research actually suggests that restoring NAD+ may improve immune surveillance against tumors by supporting T-cell function. Nonetheless, individuals with active cancer should consult their oncologist before supplementing with any NAD+ precursor.
NAD+ precursors may also interact with the broader landscape of senolytic therapies and other longevity interventions. Some researchers have speculated that combining NAD+ boosters with senolytics or autophagy-enhancing strategies could produce synergistic anti-aging effects, though this remains an active area of investigation.
How to Choose Between NMN and NR
The honest answer is that, based on current evidence, neither NMN nor NR has been definitively proven superior for human longevity outcomes. Both raise NAD+ levels, both are well-tolerated, and both have credible scientific backing. Your choice may come down to practical considerations:
- If you value regulatory clarity and established safety data: NR (particularly the Niagen brand) has the most extensive human trial history and regulatory approvals.
- If you prefer a direct pathway to NAD+ and competitive pricing: NMN offers a one-step conversion and has become more affordable as the market matures.
- If you want the most-studied option for metabolic health: The Yoshino et al. (2021) study specifically showed NMN's effects on insulin sensitivity, while NR's Martens et al. (2018) study focused on cardiovascular markers.
- If you are new to NAD+ supplementation: Either is a reasonable starting point. Begin with the lower end of the dosing range and assess tolerability over 4–8 weeks.
Regardless of which precursor you choose, purchasing from a manufacturer that provides third-party certificates of analysis (COA) is essential. Independent testing for purity, potency, and the absence of contaminants should be non-negotiable. Consulting with a healthcare professional before beginning any new supplement regimen is always recommended, especially if you have existing health conditions or take prescription medications.
Frequently Asked Questions
Can I take NMN and NR together?
While there is no published clinical evidence that combining NMN and NR provides additional benefits over either alone, some longevity enthusiasts do stack them. Since NR is converted to NMN before becoming NAD+, taking both simultaneously may simply increase the total precursor pool without a synergistic effect. If you choose to combine them, reduce the dose of each to stay within established safety ranges and consult a healthcare provider.
How long does it take for NMN or NR to raise NAD+ levels?
Clinical studies have detected increases in blood NAD+ metabolites within hours of a single dose, with sustained elevation seen within days to weeks of daily supplementation. The Martens et al. (2018) study showed significant NAD+ increases after six weeks of NR supplementation. Subjective improvements in energy and well-being, reported anecdotally by users, typically emerge within two to four weeks, though individual responses vary.
Are there food sources of NMN and NR?
Both compounds occur naturally in food, but in very small amounts. NMN is found in broccoli (0.25–1.12 mg per 100 g), edamame, cabbage, and avocado. NR is found in trace amounts in cow's milk. The quantities available through diet are far below the doses used in clinical studies (hundreds of milligrams per day), which is why supplementation is the primary strategy for meaningfully boosting NAD+ levels.
Should young people supplement with NAD+ precursors?
NAD+ decline is most pronounced after age 40, and most clinical trials have enrolled middle-aged and older adults. There is currently limited evidence to support NAD+ supplementation in healthy young adults (under 30) whose NAD+ levels are presumably still robust. Younger individuals may benefit more from lifestyle strategies like regular exercise, adequate sleep, and caloric moderation, which naturally support NAD+ metabolism. That said, some researchers speculate that early supplementation could be preventive, though this remains unproven.
References
- Yoshino J, Baur JA, Imai SI. Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women. Science. 2021;372(6547):1224-1229.
- Martens CR, Denman BA, Mazzo MR, et al. Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults. Nat Commun. 2018;9:1286.
- Verdin E. NAD+ in aging, metabolism, and neurodegeneration. Science. 2015;350(6265):1208-1213.